| 000 | 01322 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250514191704.0 | ||
| 264 | 0 | _c20040709 | |
| 008 | 200407s 0 0 eng d | ||
| 022 | _a1049-9091 | ||
| 024 | 7 |
_a10.1177/104990910402100313 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPrommer, Eric | |
| 245 | 0 | 0 |
_aGefitinib: a new agent in palliative care. _h[electronic resource] |
| 260 |
_bThe American journal of hospice & palliative care _c |
||
| 300 |
_a222-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEpidermal Growth Factor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aGefitinib |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPalliative Care _xstandards |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aQuinazolines _xpharmacology |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 773 | 0 |
_tThe American journal of hospice & palliative care _gvol. 21 _gno. 3 _gp. 222-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/104990910402100313 _zAvailable from publisher's website |
| 999 |
_c14895767 _d14895767 |
||